Page 8 - Dyslipidaemia_newsletter8_2024_Final

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #8 2024

Early identification of high Lp(a) through screening, aggressive
management of other risk factors, and the emergence of CLINICAL PEARLS FROM THE FACULTY Dyslipidaemia
promising Lp(a)-lowering therapies hold potential for reducing
the burden of CVD associated with elevated Lp(a).

WATCH
PROF. SANDIN DISCUSS THE
CLICK HERE CLINICAL RELEVANCE OF THIS
FOR THE LINK TO FULL ARTICLE ARTICLE.

TREATMENT

A real-world analysis of adherence, biochemical outcomes, and healthcare costs
in patients treated with rosuvastatin/ezetimibe as single-pill combination vs. free
combination in Italy.

Zambon A, et al. Eur Heart J Open. 2024 Aug 28;4(5):oeae074.

High LDL-C levels are a primary risk factor for cardiovascular disease. Achieving target LDL-C levels through lipid-lowering therapies
is crucial in CVD prevention and poor adherence hinders the achievement of LDL-C goals. Combination therapies that include
ezetimibe with a statin have been shown to be more effective at lowering LDL-C and reaching target levels than increasing statin
dosage alone.

In this real-world study examining an administrative database, 25,886 patients on a single-pill combination (SPC) of rosuvastatin and
ezetimibe, and 7309 patients on free combination treatment (FCT) of the same drugs, were identified and included in the analysis.
Adherence was calculated as the
proportion of days covered (PDC) Graphical abstract
after cohort balancing by propensity
score matching. The aim was to
compare an SPC to a FCT across
medication adherence, lipid goal
attainment, and healthcare costs.

The study found that the SPC
formulation resulted in significantly
higher adherence rates, a greater
likelihood of achieving target LDL
cholesterol levels, and overall lower
healthcare expenses compared to
FCT across all cardiovascular risk
categories.

TABLE OF CONTENTS